mild dementia | Alzheimer's, ADHD, Autism, Brain Injury Treatment, Mood Disorders New Jersey: The NeuroCognitive Institute

Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION

Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease Tel Aviv, Israel, September 14, 2016 Neurim Pharmaceuticals (“Neurim”) announced today that the first patients hav
Read More